News | Prostate Cancer | March 05, 2020

Adding MRI-targeted Biopsy Leads to More Reliable Diagnosis of Aggressive Prostate Cancer

Use of this method may allow more patients to safely elect active surveillance rather than immediate treatment of low-risk cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers

M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center

Using a combination of magnetic resonance imaging (MRI) to target and sample suspicious prostate tissue along with a standard prostate biopsy is significantly more likely to detect the most aggressive prostate cancers than standard biopsy alone

M. Minhaj Siddiqui, M.D., FACS, is associate professor of surgery at the University of Maryland School of Medicine and director of urologic oncology and robotic surgery at the University of Maryland Greenebaum Comprehensive Cancer Center. Image courtesy of University of Maryland School of Medicine

March 5, 2020 — Using a combination of magnetic resonance imaging (MRI) to target and sample suspicious prostate tissue along with a standard prostate biopsy is significantly more likely to detect the most aggressive prostate cancers than standard biopsy alone. This finding, published today in the New England Journal of Medicine, could allow a higher percentage of prostate cancer patients to avoid unnecessary treatment for slow-growing prostate cancers that are not likely to spread.

The new study was conducted by National Cancer Institute (NCI) researchers including one who is now at the University of Maryland School of Medicine (UMSOM).

"This study demonstrated that using a combination of both types of biopsies leads to more detection of prostate cancers and is less likely to miss aggressive cancers that can spread and kill," says study co-author M. Minhaj Siddiqui, M.D., FACS, an associate professor of surgery at UMSOM and a collaborating member of the NCI research team. "This is an important finding that will be practice-changing as we see more cancer centers adopting both types of biopsy methods. Those of us who have already adopted this cutting-edge technology can now give physicians and patients alike the confidence that their prostate cancer diagnosis is accurate and that hard-to- diagnose aggressive cancers are not being missed."

About one in nine men will be diagnosed with prostate cancer during his lifetime, according to the American Cancer Society. Most men diagnosed with prostate cancer do not die from it, and many have milder forms of the disease that do not require immediate treatment but can instead be carefully monitored, called active surveillance, to make sure the tumor is not growing or becoming more aggressive.

Traditional biopsies, that use ultrasound imaging to locate the gland and randomly remove 12 core tissues samples, have been known to miss aggressive cancers, however, so doctors have not felt comfortable relying on them for treatment guidance for fear of under-treating patients with deadly tumors. As a result, many men with milder forms of the disease have been over-treated with surgery or radiation which often leads to side effects such as impotence and incontinence.

In a targeted biopsy, MRIs of the suspected cancer are fused with real-time ultrasound images, creating a map of the prostate that enables doctors to pinpoint and test suspicious areas.

"With greater confidence in our ability to make an accurate diagnosis, we are better able to use more conservative approaches, such as active surveillance, to manage patients sparing them adverse side effects," said Siddiqui, who is also Director of Urologic Oncology and Robotic Surgery at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The NCI-designated comprehensive cancer center offers MRI-targeted biopsy, with expanded treatment options, including focal therapy to surgically remove only the tumor, sparing the prostate.

For the study, Siddiqui and his colleagues evaluated 2,103 men who all had both traditional biopsies using ultrasound and targeted biopsies guided by MRIs to check for prostate cancer. They then examined the prostate glands of 404 of these patients who were diagnosed with prostate cancer and had their gland surgically removed; they found that aggressive cancers went undetected in 16.8 percent of the standard biopsies compared to 8.8 percent of MRI-targeted biopsies; when the two biopsy methods were combined, only 3.5 percent of aggressive cancers were missed.

"These findings suggest that combined biopsy provides improved diagnostic accuracy over either systemic or MRI-targeted biopsy alone and better predicts the result of final histopathological analysis," the researchers wrote in the study.

The NCI conducted the study with data collected from June 2007 to January 2019. In 2015, the same group of researchers published a study in JAMA that found that 30 percent more high-risk prostate cancers were diagnosed with MRI-targeted biopsy than with the traditional approach. In addition, 17 percent fewer low-risk cancers were diagnosed with the MRI-targeted biopsy, compared to the standard method. Siddiqui was the first author of the JAMA article. It led to large cancer institutions, such as UMGCCC, adopting both biopsy methods as the standard of care.

For more information: www.umms.org/ummc

Related Content

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020
October 27, 2020 – Magn...
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

Feature | CT Angiography (CTA) | October 23, 2020
October 22, 2020 – In the FORECAST randomized clinical trial, the use of ...
This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...